- $32.92m
- -$38.36m
- 21
- 49
- 14
- 18
Annual balance sheet for Immuneering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 13.8 | 37.1 | 149 | 106 | 85.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.21 | 0.5 | 0.246 | 0.012 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 14.1 | 37.7 | 152 | 109 | 89.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.035 | 0.677 | 6.13 | 5.78 | 5.4 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 14.1 | 38.4 | 167 | 122 | 103 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.505 | 2.26 | 5.63 | 8.05 | 7.85 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.02 | 2.8 | 10.7 | 12.5 | 12 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 10.1 | 35.6 | 156 | 110 | 90.6 |
Total Liabilities & Shareholders' Equity | 14.1 | 38.4 | 167 | 122 | 103 |
Total Common Shares Outstanding |